A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 12 Aug 2017
At a glance
- Drugs Ribociclib (Primary)
- Indications Adenocarcinoma; Breast cancer
- Focus Therapeutic Use
- Acronyms EarLEE-1
- Sponsors Novartis Pharmaceuticals
- 28 Jul 2017 Planned End Date changed from 21 Aug 2023 to 13 Sep 2023.
- 28 Jul 2017 Planned primary completion date changed from 21 Aug 2023 to 13 Sep 2023.
- 28 Jun 2017 Planned End Date changed from 31 Jul 2023 to 21 Aug 2023.